medwireNews: People with type 2 diabetes who lose weight while taking semaglutide have a parallel improvement in their health-related quality of life (HRQoL), particularly that related to physical exertion, report the STEP 2 investigators at the virtual ADA 81st Scientific Sessions.
The prespecified analysis made use of the 1210 trial participants’ responses on the Short Form (SF)-36 general HRQoL questionnaire and the obesity-specific IWQOL-Lite-CT tool, used for the first time in the STEP trials.
Researcher Domenica Rubino (Washington Center for Weight Management and Research, Arlington, Virginia, USA) noted that HRQoL is often impacted by the presence of obesity, and can be even more so in people who also have diabetes, due to the accompanying comorbidities, making it an important factor to assess in intervention trials.
She reported significant improvements for semaglutide 2.4 mg/week versus placebo among the STEP 2 participants for all domains of both QoL tools. More people taking semaglutide than placebo achieved a clinically meaningful improvement in QoL, most notably for the physical functioning domains.
Presenting a closer look at these findings, Sean Wharton (Wharton Medical Clinic, Burlington, Ontario, Canada) revealed that the improvements in physical function correlated with the amount of weight lost.
He also reported that, for the SF-36 physical function domain, the greatest improvements were for vigorous activity and climbing several flights of stairs. For the obesity-specific IWQOL-Lite-CT questionnaire, the degree of improvement was similar for all activities.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group
ADA Scientific Sessions; 25–29 June 2021 (Abstract 84-OR)
ADA Scientific Sessions; 25–29 June 2021 (Abstract 85-OR)